Oligoclonal free light chains in cerebrospinal fluid as markers of intrathecal inflammation. Comparison with oligoclonal igG

Biomedical Papers

Volumn 159, Issue 1, 2015, Pages 104-113

  Zeman, David ^a,b   Hradilek, Pavel ^b   Kusnierova, Pavlina ^a,b   Piza, Radim ^b   Reguliova, Katarina ^b   Woznicova, Ivana ^b   Zapletalova, Olga ^b  

^a UNIVERSITY OF OSTRAVA   (Czech Republic)

^b UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

Author keywords

Cerebrospinal fluid; Oligoclonal free light chains; Oligoclonal IgG

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN G; OLIGOCLONAL BAND;

CEREBROSPINAL FLUID; COMPARATIVE STUDY; HUMAN; MULTIPLE SCLEROSIS; REPRODUCIBILITY;

BIOMARKERS; HUMANS; IMMUNOGLOBULIN G; MULTIPLE SCLEROSIS; OLIGOCLONAL BANDS; REPRODUCIBILITY OF RESULTS;

EID: 84924506730     PISSN: 12138118     EISSN: 18047521     Source Type: Journal    
DOI: 10.5507/bp.2014.058     Document Type: Article

References (62)

1. Sindic CJ, Van Antwerpen MP, Goffette S. The intrathecal humoral immune response: laboratory analysis and clinical relevance. Clin Chem Lab Med 2001;39:333-40.
2. Link H, Huang YM. Oligoclonal bands in multiple sclerosis cerebro- spinal fluid: An update on methodology and clinical usefulness. J Neuroimmunol 2006;180:17-28.
3. Sindic CJ, Laterre EC. Oligoclonal free kappa and lambda bands in the cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases. An immunoaffinity-mediated capillary blot study. J Neuroimmunol 1991;33:63-72.
4. Goffette S, Schluep M, Henry H, Duprez T, Sindic CJ. Detection of oligoclonal free kappa chains in the absence of oligoclonal IgG in the CSF of patients with suspected multiple sclerosis. J Neurol Neurosurg Psychiatry 2004;75:308-10.
5. Lamers KJ, de Jong JG, Jongen PJ, Kock-Jansen MJ, Teunesen MA, Prudon-Rosmulder EM. Cerebrospinal fluid free kappa light chains versus IgG findings in neurological disorders: qualitative and quan- titative measurements. J Neuroimmunol 1995;62:19-25.
6. Krakauer M, Schaldemose Nielsen H, Jensen J, Sellebjerg F. Intrathecal synthesis of free immunoglobulin light chains in mul- tiple sclerosis. Acta Neurol Scand 1998;98:161-5.
7. Bracco F, Gallo P, Menna R, Battistin L, Tavolato B. Free light chains in the CSF in multiple sclerosis. J Neurol 1987;234:303-7.
8. Gallo P, Tavolato B, Bergenbrant S, Sidén Ǻ. Immunoglobulin light chain patterns in the cerebrospinal fluid. A study with special refer- ence to the occurrence of free light chains in cerebrospinal fluid with and without oligoclonal immunoglobulin G. J Neurol Sci 1989;94:241-53.
9. Gallo P, Piccinno MG, De Rossi A, Pagni S, Amadori A, Chieco-Bianchi L, Tavolato B. Free light chains of immunoglobulins in the cerebro-spinal fluid of human immunodeficiency virus type 1-infected pa- tients. J Neuroimmunol 1990;26:229-38.
10. Lolli F, Siracusa G, Amato MP, Fratiglioni L, Dal Pozzo G, Galli E, Amaducci L. Intrathecal synthesis of free immunoglobulin light chains and IgM in initial multiple sclerosis. Acta Neurol Scand 1991;83:239-43.
11. Vakaet A, Thompson EJ. Free light chains in the cerebrospinal fluid: an indicator of recent immunological stimulation. J Neurol Neurosurg Psychiatry 1985;48:995-8.
12. McLean BN, Miller D, Thompson EJ. Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behçet’s dis- ease involving the nervous system. J Neurol Neurosurg Psychiatry 1995;58:548-54.
13. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for mul- tiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
14. Mayringer I, Timeltaler B, Deisenhammer F. Correlation between the IgG index, oligoclonal bands in CSF, and the diagnosis of demyelin-ating diseases. Eur J Neurol 2005;12:527-30.
15. Bourahoui A, de Seze J, Guttierez R, Onraed B, Hennache B, Ferriby D, Stojkovic T, Vermersch P. CSF isoelectrofocusing in a large cohort of MS and other neurological diseases. Eur J Neurol 2004;11:525-9.
16. Wurster U. The clinical significance of an intrathecal monoclonal immunoglobulin band: A follow up study. Letter to the Editor. Neurology 2004;62:1237.
17. Lourenco P, Shirani A, Saeedi J, Oger J, Schreiber WE, Tremlett H. Oligoclonal bands and cerebrospinal fluid markers in multiple scle-rosis: associations with disease course and progression. Mult Scler 2012;19:577-84.
18. Miller DH, Weinshenker BG, Filippi M, Banvell BL, Cohen JA, Freedman MS, Galetta SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, Panitch H, Richert JR, Reingold SC, Polman CH. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008;14:1157-74.
19. Zeman D, Hradílek P, Švagera Z, Mojžíšková E, Woznicová I, Zapletalová O.. Detection of oligoclonal IgG kappa and IgG lambda using Hevylite antibodies. Comparison with oligoclonal free light chain pattern. Fluids Barriers CNS 2012;9:5.
20. Knisley KA, Rodkey LS. Affinity immunoblotting. High resolution isoelectric focusing analysis of antibody clonotype distribution. J Immunol Methods 1986;95:79-87.
21. Ikegati N, Kennet RH. Glutaraldehyde fixation of the primary anti- body-antigen complex on nitrocelulose paper increases the overall sensitivity of immunoblot assay. J Immunol Methods 1989;124:205-10.
22. Olsson T, Kostulas V, Link H. Improved detection of oligoclonal IgG in cerebrospinal fluid by isoelectric focusing in agarose, double-antibody peroxidase labeling, and avidin-biotin amplification. Clin Chem 1984;30:1246-9.
23. Sádaba MC, González-Porqué P, Masjuan J, Álvarez-Cermeño JC, Bootello A, Villar LM. An ultrasensitive method for the detection of oligoclonal IgG bands. J Immunol Methods 2004;284:141-5.
24. Andersson M, Alvarez-Cermeño J, Bernardi G, Cogato I, Fredman P, Frederiksen J, Fredrikson S, Gallo P, Grimaldi LM, Grønning M, Keir G, Lamers K, Link H, Magalhães A, Massaro AR, Öhman S, Reiber H, Rönnbäck L, Schluep M, Schuller E, Sindic CJ, Thompson EJ, Trojano M, Wurster U. Cerebrospinal fluid in the diagnosis of multiple sclero- sis: a consensus report. J Neurol Neurosurg Psychiatry 1994;57:897-902.
25. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, Öhman S, Racke MK, Sharief M, Sindic CJ, Sellebjerg F, Tourtellotte WW. Recommended standard of cere- brospinal fluid analysis in the diagnosis of multiple sclerosis. Arch Neurol 2005;62:865-70.
26. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a non-parametric approach. Biometrics 1988;44:837-45.
27. Novackova L, Zeman D. Detection of oligoclonal IgG bands in cerebrospinal fluid and serum: comparison between commercial im- munofixation method and home-made affinity immunoblotting method and evaluation of interobserver agreement. Klin Biochem Metab 2011;19:229-33.
28. Lin MW, Suan D, Lenton K, Henniker T, Burke T, Vucic S, Fulcher DA. Differentiating patterns of oligoclonal banding in the cerebrospinal fluid improves diagnostic utility for multiple sclerosis. Pathology 2012;44:248-50.
29. Davies G, Keir G, Thompson EJ, Giovannoni G. The clinical signifi- cance of an intrathecal monoclonal immunoglobulin band: a follow-up study. Neurology 2003;60:1163-6.
30. Franciotta D, Bergamaschi R, Amato MP, Zardini E, Persico A, Portaccio E, Lolli F. Clinical correlations of CSF single IgG bands. J Neurol 2005;252:1274-5.
31. Absalom S, Shah S. Differentiating patterns of oligoclonal banding in the cerebrospinal fluid and the diagnosis of multiple sclerosis. Pathology 2013;45:441-2.
32. Dobson R, Ramagopalan S, Davis A, Giovannoni G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry 2013;84:909-14.
33. Arneth B, Birklein F. High sensitivity of free lambda and free kappa light chains for detection of intrathecal immunoglobulin synthesis in cerebrospinal fluid. Acta Neurol Scand 2009;119:39-44.
34. Reiber H. Free light chains in CSF - pushing a method with biased in-terpretations. Letter to the editor. Acta Neurol Scand 2009;120:445-6.
35. Arneth B. Author’s response to professor Reiber’s second letter con-cerning our article: High sensitivity of free lambda and free kappa light chains for the detection of intrathecal immunoglobulin syn- thesis in cerebrospinal fluid. Acta Neurol Scand 2009; 120:451-2.
36. Tumani H, Deisenhammer F, Giovannoni G, Gold R, Hartung HP, Hemmer B, Hohlfeld R, Otto M, Stangel M, Wildemann B, Zettl UK. Revised McDonald kriteria: the persisting importance of cerebrospi- nal fluid analysis. Letter to the Editor. Ann Neurol 2011;70:520.
37. Tintoré M, Rovira A, Río J, Tur C, Pelayo R, Nos C, Téllez N, Perkal H, Comabella M, Sastre-Garriga J, Montalban X. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 2008;70:1079-83.
38. Zipoli V, Hakiki B, Portaccio E, Lolli F, Siracusa G, Giannini M, Pantoni L, Pescini F, Sorbi S, Amato MP. The contribution of cerebrospinal fluid oligoclonal bands to the early diagnosis of multiple sclerosis. Mult Scler 2009;15:472-8.
39. Kaplan B, Aizenbud BM, Golderman S, Yaskariev R, Sela BA. Free light chain monomers in the diagnosis of multiple sclerosis. J Neuroimmunol 2010;229:263-71.
40. Kaplan B, Golderman S, Yahalom G, Yeskaraev R, Ziv T, Aizenbud BM, Sela BA, Livneh A. Free light chain monomer-dimer patterns in the diagnosis of multiple sclerosis. J Immunol Methods 2013;390:74-80.
41. Rudick RA, Medendorp SV, Namey M, Boyle S, Fischer J. Multiple sclerosis progression in a natural history study: Predictive value of cerebrospinal fluid free kappa light chains. Mult Scler 1995;1:150-5.
42. Rinker JR, Trinkaus K, Cross AH. Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis. Neurology 2006;67:1288-90.
43. Thompson EJ. Quality versus quantity: Which is better for cerebro- spinal fluid IgG? Clin Chem 2004;50:1721-2.
44. Keir G, Barrio S, Thompson EJ. Discrepancies between qualitative and quantitative analysis of cerebrospinal fluid IgG: densitometric comparison of nephelometry-silver versus immuno-enzymes. Ann Clin Biochem 2008;45:404-8.
45. Nakano T, Miyazaki S, Takahashi H, Matsumori A, Maruyama T, Komoda T, Nagata A. Immunochemical quantification of free im-munoglobulin light chains from an analytical perspective. Clin Chem Lab Med 2006;44:522-32.
46. Fagnart OC, Sindic CJM, Laterre C. Free kappa and lambda light chain levels in the cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases. J Neuroimmunol 1988;19:119-32.
47. Lolli F, Amaducci L. Measurement of free kappa immunoglobulin blight chains in the cerebrospinal fluid by a competitive avidin-biotin ELISA. Clin Chim Acta 1989;182:229-34.
48. Fischer C, Arneth B, Koehler J, Lotz J, Lackner KJ. Kappa free light chains in cerebrospinal fluid as markers of intrathecal immuno-globulin synthesis. Clin Chem 2004;50:1809-13.
49. Desplat-Jégo S, Feuillet L, Pelletier J, Bernard D, Chériff AA, Boucraut J. Quantification of immunoglobulin free light chains in cerebrospi-nal fluid by nephelometry. J Clin Immunol 2005;25:338-45.
50. Presslauer S, Milosavljevic D, Brücke T, Bayer P, Hübl W. Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis. J Neurol 2008;255:1508-14.
51. Villar LM, Espiño M, Costa-Frossard L, Muriel A, Jiménez J, Álvarez- Cermeño JC. High levels of cerebrospinal fluid free kappa chains predict conversion to multiple sclerosis. Clin Chim Acta 2012;413:1813-6.
52. Presslauer S, Milosavljevic D, Huebl W, Parigger S, Schneider-Koch G, Bruecke T. Kappa free light chains: diagnostic and prognostic rel-evance in MS and CIS. PLoS One 2014;9(2):e89945.
53. Senel M, Tumani H, Lauda C, Presslauer S, Mojib-Yezdani R, Otto M, Brettschneider J. Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis. PLoS One 2014;9(4):e88680.
54. Groot Kormelink T, Blokhuis BR, Kil L, Hendriks R, Redegeld FA. Immunoglobulin free light chain monomers and dimers are differentially secreted by plasma cells and are functionally distinct. In: Groot Kormelink T. Immunoglobulin free light chains in inflam- matory diseases. New findings on FLCs fitted into current concepts of immune regulation. Thesis. GVO/Ponson & Looijen B.V., Ede, The Netherlands 2012:187-203.
55. Kaplan B, Ramirez-Alvarado M, Dispenzieri A, Zeldenrust SR, Leung N, Livneh A, Gallo G. Isolation and biochemical characterization of plasma monoclonal free light chains in amyloidosis and multiple myeloma: a pilot study of intact and truncated forms of light chains and their charge properties. Clin Chem Lab Med 2008;46:335-41.
56. Contini C, Gainardi E, Cultrera R, Seraceni S, Castellazi M, Peyron F, Granieri E. Evidence of cerebrospinal fluid free kappa light chains in AIDS patients with Toxoplasma gondii encephalitis. J Neuroimmunol 2000;108:221-6.
57. Villar LM, Sádaba MC, Roldán E, Masjuan J, González-Porqué P, Villarrubia N, Espiño M, García-Trujillo JA, Bootello A, Alvarez-Cermeño JC. Intrathecal synthesis of oligoclonal IgM against my- elin lipids predicts an aggressive disease course in MS. J Clin Invest 2005;115:187-94.
58. Anderson TJ, Donaldson IM, Sheat JM, George PM. Methyl- prednisolone in multiple sclerosis exacerbation: changes in CSF parameters. Aust N Z J Med 1990;20:794-7.
59. Mares J, Muchova B, Herzig R, Urbanek K. Changes in the pattern of oligoclonal bands in the cerebrospinal fluid of patients with multiple sclerosis during therapy with beta interferons, and glat- iramer acetate respectively. Pilot study. Ces a Slov Neurol Neurochir 2003;66/99:118-20.
60. Von Glehn F, Farias AS, de Oliveira AC, Damasceno A, Longhini AL, Oliveira EC, Damasceno BP, Santos LM, Brandao CO. Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients. Mult Scler 2012;18:1038-41.
61. Tourtellotte WW. The cerebrospinal fluid in multiple sclerosis. In: Vinken JP, Bruyn GW, Klawans HL, Koetsier JC, editors. Handbook of Clinical Neurology Vol. 47. Demyelinating diseases. Rev. ser. 3. Amsterdam: Elsevier; 1985. p. 79-130.
62. Rudick RA, Cookfair DL, Simonian NA, Ransohoff RM, Richert JR, Jacobs LD, Herndon RM, Salazar AM, Fischer JS, Granger CV, Goodkin DE, Simon JH, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munchsauer FE, O’Reilly K, Priore RL, Pullicino PM, Scherokman BJ, Wende K, Weinstock-Guttman B, Whitham RH, The Multiple Sclerosis Collaborative Research Group. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFN-beta 1a) for relapsing multiple sclerosis. J Neuroimmunol 1999;93:8-14.